Text this: Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer

 ______      ___                ______    ______  
|      \\   / _ \\      ___    /_   _//  /_   _// 
|  --  //  | / \ ||    /   ||   -| ||-     | ||   
|  --  \\  | \_/ ||   | [] ||   _| ||_    _| ||   
|______//   \___//     \__ ||  /_____//  /__//    
`------`    `---`       -|_||  `-----`   `--`     
                         `-`